IDYA and Servier dose first patient in OptimUM-11 Phase 3 uveal melanoma trial
IDEAYA Biosciences and Servier announced the first patient was dosed in OptimUM-11, a Phase 3 registrational trial evaluating darovasertib and crizotinib as adjuvant therapy for uveal melanoma.
This is a real-time flash headline. A verified provider body is not available, so SquawkNews does not present it as a full article.